Intraindividual Comparison Between [
PSMA
multiparametric MRI
positron-emission tomography
prostate cancer
radiation therapy
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
20
02
2022
accepted:
25
05
2022
entrez:
1
8
2022
pubmed:
2
8
2022
medline:
2
8
2022
Statut:
epublish
Résumé
Accurate detection and segmentation of the intraprostatic gross tumor volume (GTV) is pivotal for radiotherapy (RT) in primary prostate cancer (PCa) since it influences focal therapy target volumes and the patients' cT stage. The study aimed to compare the performance of multiparametric resonance imaging (mpMRI) with [ In total, 93 patients from two German University Hospitals with [ In the Freiburg cohort ( Intraprostatic GTV segmentation based on [18F] PSMA-1007 PET results in more and larger GTVs compared to mpMRI. This influences focal RT target volumes and cT stage definition, but not the NCCN risk group.
Identifiants
pubmed: 35912219
doi: 10.3389/fonc.2022.880042
pmc: PMC9329567
doi:
Types de publication
Journal Article
Langues
eng
Pagination
880042Informations de copyright
Copyright © 2022 Marinescu, Spohn, Kiefer, Bronsert, Ceci, Holzschuh, Sigle, Jilg, Rühle, Sprave, Nicolay, Winzer, Rehm, Kotzerke, Hölscher, Grosu, Ruf, Benndorf and Zamboglou.
Déclaration de conflit d'intérêts
CZ received funding from the German Cancer Consortium (DKTK), Naslund Medical, and the Klaus Tschira foundation, as well as honoraria from Johnson and Johnson and Novocure, outside the submitted work. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Theranostics. 2017 Jan 1;7(1):228-237
pubmed: 28042330
Radiat Oncol. 2018 May 2;13(1):81
pubmed: 29716617
Sci Rep. 2021 Mar 12;11(1):5836
pubmed: 33712662
Front Oncol. 2020 Dec 07;10:600690
pubmed: 33365271
Prostate Cancer Prostatic Dis. 2021 Jun;24(2):423-430
pubmed: 32999466
Eur Urol. 2019 May;75(5):712-720
pubmed: 30509763
Eur J Nucl Med Mol Imaging. 2021 Sep;48(10):3315-3324
pubmed: 33620559
Eur Urol. 2021 Dec;80(6):682-689
pubmed: 34465492
Cancers (Basel). 2021 Nov 18;13(22):
pubmed: 34830950
Eur Urol. 2017 Apr;71(4):618-629
pubmed: 27568654
Eur Urol. 2016 Nov;70(5):829-836
pubmed: 26795686
Radiother Oncol. 2018 Apr;127(1):49-61
pubmed: 29496279
Lancet. 2020 Apr 11;395(10231):1208-1216
pubmed: 32209449
J Nucl Med. 2019 Jul;60(7):944-949
pubmed: 30552201
Eur J Nucl Med Mol Imaging. 2020 Nov;47(12):2796-2803
pubmed: 32342192
Front Oncol. 2020 Nov 23;10:596756
pubmed: 33330088
J Urol. 2017 Feb;197(2):320-326
pubmed: 27484386
Pharmaceuticals (Basel). 2014 Jun 30;7(7):779-96
pubmed: 24983957
Front Oncol. 2021 May 14;11:652678
pubmed: 34055621
Eur J Nucl Med Mol Imaging. 2021 Jun;48(6):1987-1997
pubmed: 33210239
J Clin Oncol. 2021 Mar 1;39(7):787-796
pubmed: 33471548
Pharmaceuticals (Basel). 2017 Sep 27;10(4):
pubmed: 28953234
N Engl J Med. 2018 May 10;378(19):1767-1777
pubmed: 29552975
Eur J Nucl Med Mol Imaging. 2022 Apr;49(5):1731-1742
pubmed: 34725727
Pathol Oncol Res. 2009 Jun;15(2):167-72
pubmed: 18802790
Nat Clin Pract Oncol. 2007 Nov;4(11):632-42
pubmed: 17965641
J Nucl Med. 2020 Apr;61(4):527-532
pubmed: 31562225
Radiother Oncol. 2019 Dec;141:214-219
pubmed: 31431366